# Open Orphan £10.4m contract with existing Big Pharma client

- Link: https://www.directorstalkinterviews.com/open-orphan-10.4m-contract-with-existing-big-pharma-client/4121078578
- Published: 2022-08-22T07:06:15+01:00
- Author: Giles

**Open Orphan plc** ([LON:ORPH](https://www.directorstalkinterviews.com/company/open-orphan-plc/orph.l)),
a rapidly growing specialist contract research organisation (CRO) and world leader
in testing infectious and respiratory disease products using human challenge clinical
trials, has today announced that hVIVO, a subsidiary of Open Orphan, has signed 
a £10.4m contract with an existing top 5 global pharmaceutical client to manufacture
a new batch of H1N1 influenza challenge virus, leveraging off an existing in-house
generated challenge model, and to conduct a human challenge trial to test the client’s
antiviral product.

hVIVO has world-leading expertise in challenge agent manufacture, with the ability
to manufacture specific subtypes of viruses, as well as unrivalled experience in
conducting challenge studies. Since the COVID-19 pandemic, the Company has seen 
an increase in the number of clients looking to test their vaccines and antivirals
against specific subtypes of viruses that are circulating in the population or that
have the potential to be widely spread. As a result, there is a greater interest
in end-to-end human challenge contracts such as this, that include a novel challenge
agent manufacture and a challenge study.

The study will evaluate the efficacy profile of the antiviral against the specific
influenza subtype, generating data quickly and efficiently. This is the third human
challenge contract signed with this client, highlighting the Company’s world leading
expertise and the clear benefits of human challenge trials to Big Pharma’s drug 
development process. 

Good Manufacturing Practice compliant virus manufacturing activities will commence
immediately and are expected to complete by Q2 2023. Once completed, hVIVO will 
conduct a Phase 2a double-blinded placebo-controlled human challenge study which
is expected to be completed by Q4 2023. hVIVO will recruit healthy volunteers via
the Company’s dedicated volunteer recruitment arm, FluCamp. The majority of revenue
from the contract is expected to be recognised during 2023.

> **Yamin ‘Mo’ Khan, Chief Executive Officer of Open Orphan, said:** _“We’re delighted
> to be working again with this top 5 global pharmaceutical company to test its 
> antiviral, using a new influenza strain developed by our highly experienced team.
> This contract is the third challenge study with this client, and our second end-
> to-end full-service contract overall. Our one-stop shop service offerings from
> manufacturing bespoke challenge agents to conducting full challenge studies is
> unique in the market. I am confident, that with our highly qualified teams and
> their clinical development expertise, we are well placed to address the growing
> infectious disease and respiratory research markets._
> _“Influenza poses a serious global health threat, causing an estimated 290,000–
> 650,000 deaths per year_ _with significant pandemic potential, and as such, the
> development of new vaccines and antivirals to fight flu remains vitally important.”_

> **Dr Andrew Catchpole, Chief Scientific Officer of hVIVO, said:** _“This contract
> is a strong example of where human challenge studies can provide significant value.
> These studies can quickly and cost-effectively generate efficacy data for our 
> clients in specific viral subtypes. As illustrated with this contract, our world-
> class manufacturing capabilities can produce a challenge agent for subtypes that
> pose a particular global health risk or are already circulating in the population.
> The resulting data can then indicate whether the candidate is viable for Phase
> II/III studies, providing substantial time and financial savings compared to traditional
> field-based studies.”_

Share on:
